Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens

NEW YORK, Aug. 1, 2011 /PRNewswire/ — Reportlinker.com
announces that a new market research report is available in its
catalogue:

Sustained Release Injectables: Evolving Formulations, Improving
Dosing Regimens

http://www.reportlinker.com/p0581172/Sustained-Release-Injectables-Evolving-Formulations-Improving-Dosing-Regimens
.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

The ability to formulate injectable drugs to increase the
duration of efficacy for a given dose and simultaneously reduce the
dosing frequency addresses several important health care issues.
Less frequent dosing is believed to improve patient safety, reduce
the incidence of injection site complications and improve
compliance with drug protocols. Sustained release formulations
mitigate the bolus effect at the time of injection, and thus have a
salutary influence on drug side effects. All of these advantages,
along with the need for fewer patient caregiver visits (for
practitioner-administered drugs) have a positive, downward impact
on overall healthcare costs. Currently approved sustained release
injectables rely on a spectrum of branded formulation technologies
to modulate the drug’s release profile post-injection. Typically
off-patent or generic drugs, they include drug therapies for almost
a dozen major therapeutic segments, including neurological
conditions, metabolic diseases, oncology, pain management and
reproductive health. As the incidence and prevalence of chronic
illnesses increases with the aging population, the attraction and
interest in sustained release injectables will increase.